Immatics N.V.
Informe acción NasdaqCM:IMTX
Capitalización de mercado: US$1.1b
Immatics Crecimiento futuro
Future controles de criterios 0/6 Se prevé que los beneficios de Immatics disminuyan a un ritmo anual de 16.4%, mientras que sus ingresos anuales crecerán a un ritmo de 7.9% por año. Se espera que el BPA disminuya en un 11.6% al año.
Información clave
-16.4%
Tasa de crecimiento de los beneficios
-11.6%
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Biotechs 27.3% Tasa de crecimiento de los ingresos 7.9% Rentabilidad financiera futura n/a Cobertura de analistas Good
Última actualización 11 Oct 2024
Actualizaciones recientes sobre el crecimiento futuro
Price target decreased by 7.9% to US$17.50 Aug 01
Consensus estimates of losses per share improve by 10% May 16
Price target increased by 8.2% to US$19.83 Nov 15
Consensus revenue estimates increase by 11%, EPS downgraded Mar 29
Price target decreased by 8.8% to US$18.25 Mar 26
Consensus EPS estimates increase by 76% Nov 24
Mostrar todas las actualizaciones Immatics N.V. has completed a Follow-on Equity Offering in the amount of $150.3125 million. Oct 12
Immatics N.V. has filed a Follow-on Equity Offering.
Immatics N.V.'s (NASDAQ:IMTX) Price Is Out Of Tune With Revenues Sep 21
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Aug 14
Price target decreased by 7.9% to US$17.50 Aug 01
Immatics N.V. Appoints Alise Reicin to Board of Directors Jul 31
Immatics (NASDAQ:IMTX) Is In A Good Position To Deliver On Growth Plans Jul 12
New major risk - Financial position May 17
First quarter 2024 earnings: EPS and revenues exceed analyst expectations May 17
Consensus estimates of losses per share improve by 10% May 16
New major risk - Revenue and earnings growth May 15
Pinning Down Immatics N.V.'s (NASDAQ:IMTX) P/S Is Difficult Right Now May 03
New major risk - Revenue and earnings growth Mar 22
Full year 2023 earnings: EPS exceeds analyst expectations Mar 21
Immatics N.V., Annual General Meeting, Jun 19, 2024 Jan 30 Immatics N.V. has completed a Follow-on Equity Offering in the amount of $175.175 million. Jan 19
Immatics N.V. has filed a Follow-on Equity Offering. Jan 18
New major risk - Revenue and earnings growth Nov 17
New major risk - Financial position Nov 16
Price target increased by 8.2% to US$19.83 Nov 15
Immatics N.V. Reports Interim Clinical Data from ACTengine IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRame in an Ongoing Phase 1 Trial Nov 09
New major risk - Revenue and earnings growth Nov 07
New major risk - Revenue and earnings growth Nov 03
Immatics N.V. Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine(R) IMA203 TCR-T Monotherapy Oct 25
We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely Sep 26
Immatics N.V. Initiates Phase 1/2 Clinical Trial to Evaluate Promame TCR Bispecific IMA402 in Patients with Advanced Solid Tumors Aug 11
We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely Jun 12
Immatics N.V., Annual General Meeting, Jun 20, 2023 May 27
First quarter 2023 earnings released: €0.26 loss per share (vs €1.36 profit in 1Q 2022) May 16
Investor sentiment improves as stock rises 42% May 04
Investor sentiment improves as stock rises 22% Apr 19
Consensus revenue estimates increase by 11%, EPS downgraded Mar 29
Price target decreased by 8.8% to US$18.25 Mar 26
Full year 2022 earnings released: EPS: €0.56 (vs €1.48 loss in FY 2021) Mar 22
Investor sentiment deteriorated over the past week Dec 15
Consensus EPS estimates increase by 76% Nov 24
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Nov 19
Immatics Reports Interim Clinical Data Update on Actengine(R) Ima203 Tcr-T Monotherapy Targeting Prame Oct 11
Immatics launches $110M stock offering Oct 10
Investor sentiment deteriorated over the past week Sep 13
Immatics N.V. Presents Comprehensive Preclinical Data Set for Tcr Bispecific Candidate Ima402 Targeting Prame At European Society for Medical Oncology (Esmo) Congress 2022 Sep 13
Immatics N.V. Announces First Cancer Patient Treated with Second-Generation Actengine(R) Tcr-T Candidate Ima203cd8 Targeting Prame Aug 24
Second quarter 2022 earnings: EPS and revenues miss analyst expectations Aug 10
Investor sentiment improved over the past week Jul 21
Cancer immunotherapy biotech Immatics up 18% on 4x normal volume Jul 19
Price target decreased to US$20.00 Jul 14
First quarter 2022 earnings: EPS and revenues miss analyst expectations Jun 03
Immatics N.V., Annual General Meeting, Jun 13, 2022 May 28
Immatics N.V. Announces First Patient Treated with Actengine® Ima203 Tcr-T in Combination with Checkpoint Inhibitor Opdivo® (Nivolumab) in Patients with Advanced Solid Tumors May 19
Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors May 12
Price target decreased to US$22.80 May 05
Forecast to breakeven in 2022 Apr 27
Forecast to breakeven in 2022 Apr 01
Forecast to breakeven in 2022 Mar 28
Consensus forecasts updated Feb 27
Here's Why We're Watching Immatics' (NASDAQ:IMTX) Cash Burn Situation Jan 29
Analysts' Revenue Estimates For Immatics N.V. (NASDAQ:IMTX) Are Surging Higher Dec 16
Consensus forecasts updated Dec 16
Third quarter 2021 earnings released: €0.43 loss per share (vs €2.61 loss in 3Q 2020) Nov 19
Second quarter 2021 earnings released: €0.38 loss per share (vs €18.08 loss in 2Q 2020) Aug 12
Supervisory Director Christof Hettich has left the company Jun 24
Supervisory Director Christof Hettich has left the company Jun 23
Consensus forecasts updated May 25
First quarter 2021 earnings released: €0.34 loss per share (vs €7.14 loss in 1Q 2020) May 19
Immatics Presents Preclinical Proof-Of-Concept Data for TCR Bispecifics Program IMA402 Targeting PRAME May 12
Full year 2020 earnings released: €4.77 loss per share (vs €0.95 loss in FY 2019) Apr 02
Immatics N.V. (NASDAQ:IMTX) Analysts Are Pretty Bullish On The Stock After Recent Results Apr 01
Immatics N.V., Annual General Meeting, Jun 17, 2021 Mar 20
Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs Mar 18
New 90-day high: US$11.56 Jan 20
What Is The Ownership Structure Like For Immatics N.V. (NASDAQ:IMTX)? Jan 18
Immatics reports Q3 results Dec 02
Immatics (IMTX) Investor Presentation - Slideshow Nov 13
New 90-day high: US$11.73 Oct 11
Immatics N.V. Announces Executive Changes Sep 30
First half earnings released Sep 06
Previsiones de crecimiento de beneficios e ingresos NasdaqCM:IMTX - Estimaciones futuras de los analistas y datos financieros pasados (EUR Millions) Fecha Ingresos Beneficios Flujo de caja libre Flujo de caja operativo Núm. de analistas medio 12/31/2026 52 -158 -171 N/A 5 12/31/2025 58 -143 -140 N/A 6 12/31/2024 81 -85 -134 N/A 6 6/30/2024 71 -74 -45 -17 N/A 3/31/2024 74 -80 -26 9 N/A 12/31/2023 54 -97 -13 18 N/A 9/30/2023 76 -84 -117 -92 N/A 6/30/2023 85 -79 -113 -94 N/A 3/31/2023 80 -68 -40 -31 N/A 12/31/2022 173 38 94 100 N/A 9/30/2022 151 34 97 102 N/A 6/30/2022 142 28 113 119 N/A 3/31/2022 130 15 38 44 N/A 12/31/2021 35 -93 -90 -85 N/A 9/30/2021 28 -95 -86 -81 N/A 6/30/2021 30 -231 -133 -127 N/A 3/31/2021 32 -226 -97 -91 N/A 12/31/2020 31 -211 -88 -81 N/A 9/30/2020 26 -208 -38 -31 N/A 6/30/2020 23 -49 75 81 N/A 3/31/2020 22 -34 55 60 N/A 12/31/2019 18 -32 69 71 N/A 12/31/2018 4 -31 20 21 N/A
Mostrar más
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que IMTX siga sin ser rentable en los próximos 3 años.
Beneficios vs. Mercado: Se prevé que IMTX siga sin ser rentable en los próximos 3 años.
Beneficios de alto crecimiento: Se prevé que IMTX siga sin ser rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (7.9% al año) de IMTX crezcan más despacio que el mercado de US (8.9% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 7.9% al año) de IMTX crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de IMTX se prevé que sea elevada dentro de 3 años.
Descubre empresas en crecimiento Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
